WhatsApp
backNews Article

Jubilant Pharmova Reports ₹685 Million Revenue and ₹76 Million Net Profit for Q2 September 2026

The company's unaudited standalone results for the quarter and half-year ended September 30, 2026, were approved and reviewed by independent auditors as per SEBI regulations.

Jubilant Pharmova Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2026. The company reported total revenue from operations of ₹685 million for Q2 and ₹1,366 million for the half year, with a net profit of ₹76 million for the quarter. The results were reviewed by Walker Chandiok & Co LLP and comply with Indian Accounting Standards.

6 days ago|JUBLPHARMA-0.36%
Jubilant Pharmova LimitedJUBLPHARMAFinancial Results

Jubilant Pharmova Limited

Financial Results

Jubilant Pharmova Limited announced its unaudited standalone and consolidated financial results for the quarter and half year ending September 30, 2026, reporting ₹685 million in revenue and ₹76 million in net profit for the quarter.

The Board of Directors approved the unaudited financial results at their meeting on November 13, 2026, for the quarter and half-year ended September 30, 2026.

For the quarter ended September 30, 2026, revenue from operations stood at ₹685 million, while the total revenue including other income was ₹694 million.

Profit before tax was ₹76 million for the quarter. After accounting for tax expenses, the net profit from continuing operations was ₹76 million.

For the half year ended September 30, 2026, revenue from operations reached ₹1,366 million with corresponding improvements in profits.

The standalone financial statements were prepared in accordance with Indian Accounting Standard 34 and reviewed by Walker Chandiok & Co LLP, who issued an unqualified review report confirming the statements comply with Listing Regulations requirements.

Highlights

  • Q2 September 2026 revenue from operations: ₹685 million
  • Q2 total income: ₹694 million
  • Profit before tax for Q2: ₹76 million
  • Net profit from continuing operations in Q2: ₹76 million
  • Half year revenue from operations: ₹1,366 million
  • Unaudited financial results approved on November 13, 2026, by the Board of Jubilant Pharmova Limited

Key Data Snapshot

Quarter ended30 September 2026
Total revenue from operations (Q2)₹685 million
Total income including other income (Q2)₹694 million
Profit before tax (Q2)₹76 million
Net profit from continuing operations (Q2)₹76 million
Half year revenue from operations₹1,366 million
Equity share capital₹159 million
Date of Board meeting13 November 2026

What happened

  • Jubilant Pharmova Limited approved its unaudited standalone and consolidated financial results for Q2 and H1 ended September 30, 2026.
  • The total revenue from operations for Q2 was ₹685 million, and net profit after tax was ₹76 million.
  • The results were considered and approved by the Board on November 13, 2026.

Key details

  • The standalone financial results comply with Indian Accounting Standard 34 as mandated under the Companies Act, 2013.
  • Walker Chandiok & Co LLP conducted a limited review of the unaudited financials and issued a report with no qualifications.
  • The total income including other income in Q2 was ₹694 million.
  • Net profit includes continuing operations; no significant discontinued operations were reported for the period.

Regulatory and governance context

  • Results were submitted as per Regulation 33 and 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
  • The company maintains compliance with applicable accounting standards and listing rules.
  • Independent auditor's limited review report was provided in accordance with Standard on Review Engagements 2410.

More News on Financial Results

View all

Latest corporate announcements and market updates in Financial Results.

View all news
Jubilant Pharmova Reports ₹685 Million Revenue and ₹76 | Stockk News